Status:
COMPLETED
Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy
Lead Sponsor:
AstraZeneca
Conditions:
Cancer
Eligibility:
All Genders
20+ years
Brief Summary
This is an observational prospective study that investigates only daily practice. The prescription of anti-cancer medicine is separated from the decision to include the patient in this study. In addit...
Eligibility Criteria
Inclusion
- At least one measurable lesion according to RECIST criteria
- Histologically or cytologically confirmed NSCLC of adeno histology
- Locally progressed or metastasized on or after first-line chemotherapy. The imaging evidence of disease progression can be either chest X ray, CT or MRI assessment on measurable lesions. If no measurable lesion is available, evaluable lesions are acce
Exclusion
- \-
Key Trial Info
Start Date :
August 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00836160
Start Date
August 1 2009
End Date
September 1 2012
Last Update
September 20 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Gueishan Township, Taiwan